Fig. 4: ID3 and CD52 can be used as markers to predict the efficacy of neoadjuvant therapies for ESCC. | Cell Death & Disease

Fig. 4: ID3 and CD52 can be used as markers to predict the efficacy of neoadjuvant therapies for ESCC.

From: A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC

Fig. 4

A Differential gene volcano map between tumor group and adjacent normal tissue group under two regimens. B Expression levels of ID3 and CD52 in ESCC tumor tissue and normal tissue. C The correlation between the expression level of ID and CD52 and the differentiation degree of ESCC shown in the histogram. D ID3, CD52 expression level and ESCC metastasis correlation histogram. E KM survival curves of ID3 and CD52. F Lollipop diagram of immune cell infiltration correlation of ID3 and CD52 in ESCC. G Bar chart for the ESTIMATE score of ID3 and CD52 in ESCC. H, I IHC analysis of the paraffin-embedded ESCC tissues using a CD52 antibody and the corresponding quantification. P < 0.05. *, P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page